价格目标

Search documents
Wall Street Analysts See a 28.33% Upside in Rambus (RMBS): Can the Stock Really Move This High?
ZACKS· 2025-06-04 15:01
Rambus (RMBS) closed the last trading session at $56.30, gaining 12.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72.25 indicates a 28.3% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $9.97. While the lowest estimate of $55 indicates a 2.3% decline from the current price level, the most optimistic analyst expects the ...
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?
ZACKS· 2025-06-04 15:01
Core Viewpoint - Zymeworks Inc. (ZYME) shows potential for significant upside, with a mean price target of $21.35 indicating a 76.7% increase from its current price of $12.08 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $7.45, indicating variability among analysts [2] - The lowest estimate is $12, suggesting a slight decline of 0.7%, while the highest estimate predicts a surge of 148.3% to $30 [2] - Analysts' price targets are often questioned for their reliability, as they may mislead investors rather than provide accurate guidance [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about ZYME's earnings, with a consensus indicating better-than-previously estimated earnings [4] - The Zacks Consensus Estimate for the current year has risen by 6.2% over the past month, with four estimates increasing and no negative revisions [12] - A strong correlation exists between earnings estimate revisions and near-term stock price movements, suggesting potential upside for ZYME [11] Zacks Rank and Investment Potential - ZYME holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [13]
Does Energy Transfer LP (ET) Have the Potential to Rally 28.1% as Wall Street Analysts Expect?
ZACKS· 2025-06-04 15:01
Energy Transfer LP (ET) closed the last trading session at $17.90, gaining 13.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $22.93 indicates a 28.1% upside potential.The average comprises 14 short-term price targets ranging from a low of $19 to a high of $26, with a standard deviation of $1.94. While the lowest estimate indicates an increase of 6.2% from the current price leve ...
How Much Upside is Left in Knot Offshore (KNOP)? Wall Street Analysts Think 106.1%
ZACKS· 2025-06-04 15:01
Shares of Knot Offshore (KNOP) have gained 0.3% over the past four weeks to close the last trading session at $6.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.17 indicates a potential upside of 106.1%.The average comprises three short-term price targets ranging from a low of $12 to a high of $15, with a standard deviation of $1.61. While the lowest estimate indicates a ...
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
ZACKS· 2025-06-04 15:01
Shares of Intellia Therapeutics, Inc. (NTLA) have gained 6.1% over the past four weeks to close the last trading session at $7.69, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $38.32 indicates a potential upside of 398.3%.The average comprises 25 short-term price targets ranging from a low of $7 to a high of $106, with a standard deviation of $24.94. While the lowest estimate ...
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
ZACKS· 2025-06-04 14:55
Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) closed the last trading session at $13.36, gaining 11.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.90 indicates a 138.8% upside potential.The average comprises 10 short-term price targets ranging from a low of $27 to a high of $38, with a standard deviation of $4.01. While the lowest estimate indicates an increase of 102.1 ...
Wall Street Analysts See a 59.92% Upside in Spire (SPIR): Can the Stock Really Move This High?
ZACKS· 2025-06-02 15:01
Shares of Spire Global, Inc. (SPIR) have gained 7.2% over the past four weeks to close the last trading session at $10.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $16.60 indicates a potential upside of 59.9%.The average comprises five short-term price targets ranging from a low of $13 to a high of $20, with a standard deviation of $2.51. While the lowest estimate indicat ...
Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet
ZACKS· 2025-06-02 15:01
Kamada (KMDA) closed the last trading session at $6.85, gaining 2.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $14.17 indicates a 106.9% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $3.13. While the lowest estimate of $11 indicates a 60.6% increase from the current price level, the most optimistic analyst expects the s ...
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?
ZACKS· 2025-06-02 15:01
Shares of Candel Therapeutics, Inc. (CADL) have gained 3.2% over the past four weeks to close the last trading session at $5.45, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21 indicates a potential upside of 285.3%.The average comprises four short-term price targets ranging from a low of $15 to a high of $25, with a standard deviation of $4.90. While the lowest estimate ind ...